Toronto, Nov. 06, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canadian based company Instadose Pharma Corp. has become the largest cultivator and pharmaceutical producer of CBD oil. The company received the only license granted in the Democratic Republic of the Congo (DRC) to import, export, cultivate and process CBD oil from cannabis. Instadose Pharma is an agricultural and pharmaceutical firm that has a partnership in traditional growing in the DRC for 5 years.
The land under cannabis cultivation is over 100,000 hectares, producing CBD Oil that is GMP certified and pharma grade 99.7% CBD. The company is the largest agricultural grower in the DRC and has a production capacity of 900,000 litres per year, with the largest agricultural presence in the entire DRC.
This news has created a non-anticipated blow to the market price of the world oil sector. If the company releases oil that is the highest quality in the world market at a price that devaluates the entire index, what will happen to all the licensed producers in this sector?
The fact is that the DRC production is the most sophisticated facilities for oil production. It is not only GMP certified but pharmaceutically accredited with EU Pharmacopeia standards. The leaders in the industry cannot produce the oil in any other regions at this price. Instadose Pharma Corp. is also located in Colombia, Argentina and Chile; however, the ideal cost of producing and growing cannabis in the DRC makes South America non-competitive.
Grant F Sanders, CEO, Instadose Pharma Corp. said: “This is a potentially a disruptive flow to the cannabis sector regarding oil production and prices. Our facilities and production will increase accordingly as the world market and prices dictate. We are selling our oil with off-take agreements worldwide including Canada, with the first release of 90,000 litres. Our firm price scale will illustrate the cost to produce in our facility. This will have a rapid effect on the industry for not only producers but the retail customer base. I have great concerns about the reaction of this news with licensed producers and the public investment sector.”
The information contained in this Press Release (“Press Release”) is being offered by Instadose Pharma Corp. (“IDP” or the “Company”) for information purposes only. This Press Release is not a prospectus, offering memorandum, advertisement, or solicitation and does not constitute or form part of, and should not be construed as, an offer or invitation to sell or any solicitation of any offer to purchase or subscribe for any securities of the Company in Canada, the United States or any other jurisdiction. Neither this Press Release, nor any part of it nor anything contained or referred to in it, nor the fact of its distribution, should form the basis of or be relied on in connection with or act as an inducement in relation to a decision to purchase or subscribe for or enter into any contract or make any other commitment whatsoever in relation to any securities of the Company. No representation or warranty, expressed or implied, is given by or on behalf of the Company, its directors and affiliates or any other person as to the accuracy or completeness of the information or opinions contained in this Press Release; and no liability whatsoever is accepted by the Company, its directors and affiliates or any other person for any loss howsoever arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith. No investment advice is offered or deemed to be offered under the Press Release, and any prospective investor should consult with his own legal, investment, accounting and tax advisors for determination of, among other things, suitability of investing in securities of the Company.